Archives

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 14 March 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an extraordinary general meeting on 14 March 2024 at 10.00 am at the Company’s premises, Skiffervägen 48 in Lund.
Biostock PHI one year CEO anniversary

BioStock: PHI “We aim to revolutionize the regenerative medicine market“

BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
PHI-at-RedEye-Regenerative-Medicine-and-Cell-Therapy-event-2024

PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024

PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
Publication-highlight

2023 publication highlights

In 2023, cell researchers all over Europe, the USA, and Asia continued to show the versatility of HoloMonitor in their innovative research. In this blog, we present the researchers behind these studies and delve into the HoloMonitor publication highlights 2023 that unlock our cells’ secrets…

PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history

PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.
Orange L929 cells on a light blue background.

Interim Report 2 2023/24

The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.

PHI appoints Pareto Securities AB to act as a liquidity provider for the Company’s share

PHI has appointed Pareto Securities as the Company’s liquidity provider.
Artistic image of molecularly imprinted polymers (MIP).

PHI granted patent on synthetic antibodies in the EU

PHI announces that the Company has been granted a patent on synthetic antibodies from the European Patent Office.

Directed issue registered at the Companies Registration Office

PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.

Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023

Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
1789101138